



## Rare Anti-Glycoenzyme Variants Leading to Recurrent Pediatric Kidney Stones

Gregory Robinson\*

*Department of Pediatrics, University of Cartagena, Cartagena, Colombia*

✉ **Gregory Robinson**

*Department of Pediatrics,  
University of Cartagena,  
Cartagena, Colombia  
E-mail: collinsg@uthscsa.co*

**Received:** 03-Jun-2025, *Manuscript No. PUCR-25-172515*; **Editor assigned:** 05-Jun-2025, *PreQC No. PUCR-25-172515 (PQ)*; **Reviewed:** 19-Jun-2025, *QC No. PUCR-25-172515*; **Revised:** 26-Jun-2025, *Manuscript No. PUCR-25-172515 (R)*; **Published:** 03-Jul-2025, *DOI: 10.14534/j-pucr.20222675703*

### Description

Pediatric nephrolithiasis has emerged as a growing concern in modern nephrology, reflecting complex interactions between genetic, metabolic, dietary, and environmental factors. While most pediatric kidney stones arise from common metabolic abnormalities such as hypercalciuria, hyperoxaluria, hypocitraturia, or cystinuria, a subset of children experience recurrent stone formation without identifiable metabolic disturbances. Recent advances in molecular nephrology have revealed that rare variants affecting glycoenzymes—enzymes responsible for carbohydrate modification and glycosylation pathways—may underlie some of these unexplained cases [1]. These anti-glycoenzyme variants interfere with post-translational modification of renal transport proteins and metabolic enzymes, disrupting solute handling and leading to persistent lithogenic conditions. Understanding the biochemical basis of these variants offers new insights into the pathogenesis of pediatric nephrolithiasis and provides potential targets for early diagnosis and personalized therapy [2].

The term “anti-glycoenzyme variant” refers to genetic or functional alterations in enzymes that catalyze the glycosylation of proteins and lipids. Glycosylation is a ubiquitous post-translational process occurring in the endoplasmic reticulum and Golgi apparatus, essential for proper folding, stability, and activity of numerous membrane transporters, receptors, and enzymes. In renal physiology, glycosylation regulates several key transporters involved in solute balance, including sodium-phosphate cotransporters, anion exchangers, and calcium-sensing receptors. Aberrant glycosylation can lead to misfolded or mislocalized proteins, impaired signal transduction, and altered ion handling—all of which can contribute to a lithogenic urinary milieu [3].

The phenotypic spectrum of anti-glycoenzyme-related nephrolithiasis is broad. Affected children often present with recurrent calcium-based stones beginning in early childhood, sometimes accompanied by mild renal tubular dysfunction, proteinuria, or low-grade metabolic acidosis. Laboratory findings may include normal serum calcium and phosphate levels, variable urinary citrate, and persistent microscopic hematuria. Because routine metabolic screening frequently yields inconclusive results, genetic analysis plays an essential role in diagnosis [4]. Whole-exome or targeted gene sequencing can identify pathogenic or likely pathogenic variants in glycosylation-related genes. Functional validation, such as enzymatic assays or glycoproteomic profiling, confirms the pathogenic mechanism by demonstrating altered glycan composition or enzyme activity.

Histopathological studies of renal tissue in these patients reveal tubular epithelial changes consistent

with sublethal injury-vacuolization, basement membrane thickening, and accumulation of misfolded glycoproteins [5]. Electron microscopy sometimes demonstrates abnormal endoplasmic reticulum distension, reflecting defective protein processing. These cellular alterations mirror those seen in Congenital Disorders of Glycosylation (CDG), a heterogeneous group of systemic metabolic diseases that also involve renal manifestations. However, in anti-glycoenzyme-related nephrolithiasis, the defects appear to be more localized or tissue-specific, possibly because of partial enzyme activity or compensatory pathways in other organs [6].

Therapeutic strategies for glycoenzyme-related kidney stones are still largely empirical. The cornerstone of management remains maintenance of high fluid intake to dilute urinary solutes and reduce crystal supersaturation. Dietary modification-lowering sodium and oxalate intake and ensuring adequate calcium consumption-is beneficial in reducing recurrence risk. Potassium citrate supplementation helps alkalinize urine and increase citrate excretion, counteracting calcium oxalate precipitation. However, in patients with documented glycosylation defects, supportive care alone may not be sufficient [7]. Emerging research suggests that supplementation with specific monosaccharides or cofactors might partially restore enzyme activity in certain variants. For example, galactose supplementation has been shown to improve glycosylation in some forms of congenital disorders of glycosylation involving galactosyltransferase deficiencies. Whether similar interventions could modify the course of glycoenzyme-related nephrolithiasis remains an open question.

In addition to metabolic management, genetic counselling is essential for affected families. Many anti-glycoenzyme variants are inherited in autosomal recessive or X-linked patterns, meaning that siblings may carry or express the mutation. Early screening of at-risk children through urinalysis and imaging can detect subclinical stone formation before significant renal damage occurs [8]. Families should also receive education on maintaining hydration, avoiding excessive dietary oxalate, and seeking prompt evaluation for flank

pain or hematuria.

The study of glycosylation defects in kidney stone disease underscores the expanding understanding of nephrolithiasis as a multifactorial disorder with deep molecular roots. Traditional views of stone formation centered on physical chemistry-the supersaturation and crystallization of solutes in urine [9]. While this remains central, contemporary research highlights the critical role of biological modulators such as proteins, enzymes, and genetic factors that govern urinary composition and crystal-cell interactions. Aberrant glycosylation alters these modulators, transforming a normally protective urinary environment into one that favours crystal adhesion and growth. This paradigm shift emphasizes the need for integrated biochemical, genetic, and proteomic approaches in evaluating unexplained or refractory pediatric stone disease.

From a research standpoint, unravelling the link between glycosylation and nephrolithiasis may open new therapeutic avenues. Small molecules that enhance glycoenzyme function, correct misfolded glycoproteins, or modulate post-translational pathways could become future treatments [10]. Gene therapy, while still in its infancy for metabolic renal diseases, holds theoretical promise for correcting enzyme defects at the source. Meanwhile, advances in urinary proteomics and glycomics could provide non-invasive biomarkers for early diagnosis, disease monitoring, and treatment response assessment.

## **Conclusion**

Rare anti-glycoenzyme variants represent an emerging category of genetic causes of recurrent pediatric kidney stones. These mutations interfere with the glycosylation of renal transporters and inhibitors of crystallization, leading to disturbances in calcium and oxalate handling, impaired tubular protection, and persistent lithogenesis. Although these variants are rare, their recognition expands the current understanding of pediatric nephrolithiasis beyond conventional metabolic explanations. Diagnostic confirmation relies on genetic testing and functional assays, while management remains largely supportive but may eventually include targeted metabolic or molecular

therapies. As genomic and proteomic technologies advance, identifying and characterizing glycosylation-related kidney stone disorders will become increasingly feasible, paving the way toward personalized interventions that prevent recurrence and preserve renal health in affected children.

### **References**

- [1] Dello Strologo L, Laurenzi C, Legato A, et al. Cystinuria in children and young adults: Success of monitoring free-cystine urine levels. *Pediatr Nephrol.* 2007;22:1869-1873.
- [2] Shoag J, Halpern J, Goldfarb DS, et al. Risk of chronic and end stage kidney disease in patients with nephrolithiasis. *J Urol.* 2014;192(5):1440-1445.
- [3] Tasian GE, Ross ME, Song L, et al. Annual incidence of nephrolithiasis among children and adults in South Carolina from 1997 to 2012. *Clin J Am Soc Nephrol.* 2016;11(3):488-496.
- [4] Harper JD, Desai AC, Maalouf NM, et al. Risk factors for increased stent-associated symptoms following ureteroscopy for urinary stones: Results from STENTS. *J Urol.* 2023;209(5):971-980.
- [5] Barreto L, Jung JH, Abdelrahim A, et al. Medical and surgical interventions for the treatment of urinary stones in children. *Cochrane Database Syst Rev.* 2019;10(10):CD010784.
- [6] Fazel M, Gubari MIM, Yousefifard M, et al. Ultrasonography in detection of renal calculi in children: A systematic review and meta-analysis. *Arch Acad Emerg Med.* 2019;7(1):e66.
- [7] Brain E, Geraghty RM, Lovegrove CE, et al. Natural history of post-treatment kidney stone fragments: A systematic review and meta-analysis. *J Urol.* 2021;206(3):526-538.
- [8] Dunmire B, Harper JD, Cunitz BW, et al. Use of the acoustic shadow width to determine kidney stone size with ultrasound. *J Urol.* 2016;195(1):171-177.
- [9] Khan SR. Nephrocalcinosis in animal models with and without stones. *Urol Res.* 2010;38(6):429-438.
- [10] Khan SR. Renal tubular damage/dysfunction: Key to the formation of kidney stones. *Urol Res.* 2006;34(2):86-91.